Posted by Michael Wonder on 20 Jan 2023
FDA approves zanubrutinib for chronic lymphocytic leukaemia or small lymphocytic lymphoma
19 January 2023 - Today the FDA approved zanubrutinib (Brukinsa, BeiGene) for chronic lymphocytic leukaemia or small lymphocytic lymphoma.
Efficacy in patients with treatment naïve chronic lymphocytic leukaemia or small lymphocytic lymphoma was evaluated in SEQUOIA.
